EUVIMEDEUVIMED entdecken
Open Access · CC0

Intranasal parainfluenza virus-vectored vaccine expressing SARS-CoV-2 spike protein of Delta or Omicron B.1.1.529 induces mucosal and systemic immunity and protects hamsters against homologous and heterologous challenge

Hong-Su Park, Yumiko Matsuoka, Celia Santos, Cindy Luongo, Xueqiao Liu, Lijuan Yang, Jaclyn A Kaiser, Eleanor F Duncan, Reed F Johnson, I-Ting Teng, Peter D Kwong, Ursula J Buchholz und 1 weitere

PLOS Pathogens · 2025

DOI: 10.1371/journal.ppat.1012585 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, 2025. Verfasst von Hong-Su Park und 12 weiteren Autor:innen. Beteiligte Einrichtung: RNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesd…. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, SARS-CoV-2, COVID-19, COVID-19 Vaccines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: Intramural NIH HHS, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, Vaccine Research Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The continuous emergence of new SARS-CoV-2 variants requires that COVID vaccines be updated to match circulating strains. We generated B/HPIV3-vectored vaccines expressing 6P-stabilized S protein of the ancestral, B.1.617.2/Delta, or B.1.1.529/Omicron variants as pediatric vaccines for intranasal immunization against HPIV3 and SARS-CoV-2 and characterized these in hamsters. Following intranasal immunization, these B/HPIV3 vectors replicated in the upper and lower respiratory tract and induced mucosal and serum anti-S IgA and IgG. B/HPIV3 expressing ancestral or B.1.617.2/Delta-derived S-6P induced serum antibodies that effectively neutralized SARS-CoV-2 of the ancestral and B.1.617.2/Delta lineages, while the cross-neutralizing potency of B.1.1.529/Omicron S-induced antibodies was lower. Despite the lower cross-neutralizing titers induced by B/HPIV3 expressing S-6P from B.1.1.529/Omicron, a single intranasal dose of all three versions of B/HPIV3 vectors was protective against matched or heterologous WA1/2020, B.1.617.2/Delta or BA.1 (B.1.1.529.1)/Omicron challenge; hamsters were protected from challenge virus replication in the lungs, while low levels of challenge virus were detectable in the upper respiratory tract of a small number of animals. Immunization also protected against lung inflammatory response after challenge, with mild inflammatory cytokine induction associated with the slightly lower level of cross-protection of WA1/2020 and B.1.617.2/Delta variants against the BA.1/Omicron variant. Serum antibodies elicited by all vaccine candidates were broadly reactive against 20 antigenic variants, but the antigenic breadth of antibodies elicited by B/HPIV3-expressed S-6P from the ancestral or B.1.617.2/Delta variant exceeded that of the S-6P B.1.1.529/Omicron expressing vector. These results will guide development of intranasal B/HPIV3 vectors with S antigens matching circulating SARS-CoV-2 variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spike Glycoprotein, CoronavirusSARS-CoV-2COVID-19COVID-19 VaccinesParainfluenza Virus 3, HumanAnimalsAdministration, IntranasalCricetinaeAntibodies, ViralImmunity, MucosalAntibodies, NeutralizingGenetic VectorsHumansMesocricetusFemale

Substanzen

Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Antibodies, ViralCOVID-19 VaccinesAntibodies, Neutralizing

Autor:innen und Institutionen

  • RNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
  • SARS-CoV-2 Virology Core, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Vaccine Research Center, Structural Virology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.

ORCID-Profile: Cyril Le Nouën

Förderung

  • Intramural NIH HHS
  • Division of Intramural Research, National Institute of Allergy and Infectious Diseases
  • Vaccine Research Center

Zitieren

APA

Park, H. S., Matsuoka, Y., Santos, C., Luongo, C., Liu, X., Yang, L., Kaiser, J. A., Duncan, E. F., Johnson, R. F., Teng, I. T., Kwong, P. D., Buchholz, U. J., & Le Nouën, C. (2025). Intranasal parainfluenza virus-vectored vaccine expressing SARS-CoV-2 spike protein of Delta or Omicron B.1.1.529 induces mucosal and systemic immunity and protects hamsters against homologous and heterologous challenge. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1012585

Vancouver

Park HS, Matsuoka Y, Santos C, Luongo C, Liu X, Yang L, et al. Intranasal parainfluenza virus-vectored vaccine expressing SARS-CoV-2 spike protein of Delta or Omicron B.1.1.529 induces mucosal and systemic immunity and protects hamsters against homologous and heterologous challenge. PLOS Pathogens. 2025. doi:10.1371/journal.ppat.1012585

BibTeX
@article{Park2025,
  author = {Park, Hong-Su and Matsuoka, Yumiko and Santos, Celia and Luongo, Cindy and Liu, Xueqiao and Yang, Lijuan and Kaiser, Jaclyn A and Duncan, Eleanor F and Johnson, Reed F and Teng, I-Ting and Kwong, Peter D and Buchholz, Ursula J and Le Nouën, Cyril},
  title = {Intranasal parainfluenza virus-vectored vaccine expressing SARS-CoV-2 spike protein of Delta or Omicron B.1.1.529 induces mucosal and systemic immunity and protects hamsters against homologous and heterologous challenge},
  journal = {PLOS Pathogens},
  year = {2025},
  doi = {10.1371/journal.ppat.1012585}
}
Kostenlos starten →